A crippling disease on the brink of global eradication. Two effective vaccines—Salk (IPV) and Sabin (OPV)—have brought the world close to elimination.
Poliomyelitis (polio) is a highly infectious viral disease that primarily affects children under 5 years of age. The virus is transmitted through contaminated water and food and multiplies in the intestine. In approximately 1 in 200 infections, the virus invades the nervous system, causing irreversible paralysis (WHO, 2024).
Global polio eradication remains a top public health priority. The WHO's Global Polio Eradication Initiative (GPEI), launched in 1988, has reduced cases by 99.9%. As of 2024, wild poliovirus remains endemic in only two countries: Afghanistan and Pakistan (CDC, 2024).
The United States has been polio-free since 1979. However, the threat of importation remains, making continued vaccination critical.
The U.S. uses IPV exclusively. Children receive doses at 2 months, 4 months, 6-18 months, and 4-6 years. Adults who are unvaccinated or have unknown status should receive 3 doses.
Vaccination remains the most effective strategy for preventing polio. The following describes established medical consensus for clinical management for those who contract infection.
No antiviral treatment exists for polio. Management is entirely supportive — pain relief, hydration, and respiratory support (including mechanical ventilation for respiratory paralysis). Early physical therapy is essential for long-term neuromuscular outcomes and reducing permanent disability. Post-polio syndrome may develop decades later and requires ongoing management.
Disclaimer: This information is for educational purposes only. Treatment decisions must be made by a qualified healthcare provider.